Surprising Analyst 12-Month Target For PTH
Dividend Channel Staff - Thursday, April 25, 9:15 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $54.40 per unit. Read More »
Fate Therapeutics Reaches Analyst Target Price
Dividend Channel Staff - Monday, March 4, 7:17 AM
Commit To Purchase Fate Therapeutics At $5, Earn 15% Annualized Using Options
Dividend Channel Staff - Wednesday, February 28, 2:42 PM
Fate Therapeutics Reaches Analyst Target Price
Dividend Channel Staff - Thursday, February 1, 6:57 AM
Analysts Predict 11% Gains Ahead For VBK
Dividend Channel Staff - Thursday, December 21, 7:12 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $263.45 per unit. Read More »
Commit To Purchase Fate Therapeutics At $2.50, Earn 30.2% Annualized Using Options
Dividend Channel Staff - Thursday, November 30, 1:47 PM
Add Up The Pieces: VB Could Be Worth $225
Dividend Channel Staff - Friday, November 17, 7:10 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap ETF (VB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $225.12 per unit. Read More »
We Did The Math KOMP Can Go To $52
Dividend Channel Staff - Wednesday, October 18, 7:01 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.03 per unit. Read More »
Sum Up The Parts: XBI Could Be Worth $138
Dividend Channel Staff - Friday, September 8, 7:22 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $137.90 per unit. Read More »
Commit To Purchase Fate Therapeutics At $2.50, Earn 34.2% Annualized Using Options
Dividend Channel Staff - Thursday, August 17, 2:02 PM
Implied VBK Analyst Target Price: $270
Dividend Channel Staff - Tuesday, August 8, 10:47 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $269.70 per unit. Read More »
Implied VHT Analyst Target Price: $287
Dividend Channel Staff - Thursday, July 6, 9:14 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $287.36 per unit. Read More »
The Implied Analyst 12-Month Target For VTWO
Dividend Channel Staff - Monday, June 5, 7:58 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $89.31 per unit. Read More »
Tuesday 1/17 Insider Buying Report: FATE
Dividend Channel Staff - Tuesday, January 17, 10:36 AM Read More »
Monday's ETF Movers: ARKK, ITA
Dividend Channel Staff - Monday, January 9, 12:03 PM Read More »
Friday Sector Laggards: Railroads, Biotechnology Stocks
Dividend Channel Staff - Friday, January 6, 12:02 PM Read More »
Monday's ETF with Unusual Volume: ESML
Dividend Channel Staff - Monday, December 12, 12:12 PM Read More »
Tuesday's ETF Movers: ARKK, OIH
Dividend Channel Staff - Tuesday, July 5, 12:00 PM Read More »
Friday's ETF Movers: SIL, ARKK
Dividend Channel Staff - Friday, June 10, 12:19 PM Read More »
Monday's ETF Movers: PSI, ARKG
Dividend Channel Staff - Monday, December 27, 12:28 PM Read More »
Tuesday's ETF Movers: ARKG, FPE
Dividend Channel Staff - Tuesday, December 7, 12:22 PM Read More »
Thursday's ETF Movers: XLE, XBI
Dividend Channel Staff - Thursday, June 6, 2:05 PM Read More »
Tuesday's ETF Movers: GXC, XBI
Dividend Channel Staff - Tuesday, July 24, 1:47 PMIn trading on Tuesday, the SPDR S&P China ETF (GXC) is outperforming other ETFs, up about 2.1% on the day. Components of that ETF showing particular strength include shares of Jinkosolar Holding (JKS), up about 6.2% and shares of Bitauto Holdings (BITA), up about 4.2% on the day. Read More »
Tuesday Sector Leaders: Gas Utilities, Biotechnology Stocks
Dividend Channel Staff - Tuesday, January 23, 1:38 PMIn trading on Tuesday, gas utilities shares were relative leaders, up on the day by about 1.2%. Leading the group were shares of Chesapeake Utilities Corporation (CPK), up about 4.7% and shares of South Jersey Industries (SJI) up about 3% on the day. Read More »
Wednesday Sector Laggards: Biotechnology, Drugs
Dividend Channel Staff - Wednesday, October 12, 12:10 PMIn trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 1.4%. Helping drag down the group were shares of Nymox Pharmaceutical (NYMX), off about 6.5% and shares of Fate Therapeutics (FATE) off about 6.1% on the day. Read More »
Wednesday Sector Laggards: Biotechnology, Drugs
Dividend Channel Staff - Wednesday, February 3, 1:12 PMIn trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Fate Therapeutics (FATE), off about 12.2% and shares of Vascular Biogenics (VBLT) off about 9.6% on the day. Read More »
Dividend Channel Staff - Thursday, April 25, 9:15 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $54.40 per unit. Read More »
Fate Therapeutics Reaches Analyst Target Price
Dividend Channel Staff - Monday, March 4, 7:17 AM
Commit To Purchase Fate Therapeutics At $5, Earn 15% Annualized Using Options
Dividend Channel Staff - Wednesday, February 28, 2:42 PM
Fate Therapeutics Reaches Analyst Target Price
Dividend Channel Staff - Thursday, February 1, 6:57 AM
Analysts Predict 11% Gains Ahead For VBK
Dividend Channel Staff - Thursday, December 21, 7:12 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $263.45 per unit. Read More »
Commit To Purchase Fate Therapeutics At $2.50, Earn 30.2% Annualized Using Options
Dividend Channel Staff - Thursday, November 30, 1:47 PM
Add Up The Pieces: VB Could Be Worth $225
Dividend Channel Staff - Friday, November 17, 7:10 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap ETF (VB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $225.12 per unit. Read More »
We Did The Math KOMP Can Go To $52
Dividend Channel Staff - Wednesday, October 18, 7:01 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Kensho New Economies Composite ETF (KOMP), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.03 per unit. Read More »
Sum Up The Parts: XBI Could Be Worth $138
Dividend Channel Staff - Friday, September 8, 7:22 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $137.90 per unit. Read More »
Commit To Purchase Fate Therapeutics At $2.50, Earn 34.2% Annualized Using Options
Dividend Channel Staff - Thursday, August 17, 2:02 PM
Implied VBK Analyst Target Price: $270
Dividend Channel Staff - Tuesday, August 8, 10:47 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $269.70 per unit. Read More »
Implied VHT Analyst Target Price: $287
Dividend Channel Staff - Thursday, July 6, 9:14 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $287.36 per unit. Read More »
The Implied Analyst 12-Month Target For VTWO
Dividend Channel Staff - Monday, June 5, 7:58 AMLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $89.31 per unit. Read More »
Tuesday 1/17 Insider Buying Report: FATE
Dividend Channel Staff - Tuesday, January 17, 10:36 AM Read More »
Monday's ETF Movers: ARKK, ITA
Dividend Channel Staff - Monday, January 9, 12:03 PM Read More »
Friday Sector Laggards: Railroads, Biotechnology Stocks
Dividend Channel Staff - Friday, January 6, 12:02 PM Read More »
Monday's ETF with Unusual Volume: ESML
Dividend Channel Staff - Monday, December 12, 12:12 PM Read More »
Tuesday's ETF Movers: ARKK, OIH
Dividend Channel Staff - Tuesday, July 5, 12:00 PM Read More »
Friday's ETF Movers: SIL, ARKK
Dividend Channel Staff - Friday, June 10, 12:19 PM Read More »
Monday's ETF Movers: PSI, ARKG
Dividend Channel Staff - Monday, December 27, 12:28 PM Read More »
Tuesday's ETF Movers: ARKG, FPE
Dividend Channel Staff - Tuesday, December 7, 12:22 PM Read More »
Thursday's ETF Movers: XLE, XBI
Dividend Channel Staff - Thursday, June 6, 2:05 PM Read More »
Tuesday's ETF Movers: GXC, XBI
Dividend Channel Staff - Tuesday, July 24, 1:47 PMIn trading on Tuesday, the SPDR S&P China ETF (GXC) is outperforming other ETFs, up about 2.1% on the day. Components of that ETF showing particular strength include shares of Jinkosolar Holding (JKS), up about 6.2% and shares of Bitauto Holdings (BITA), up about 4.2% on the day. Read More »
Tuesday Sector Leaders: Gas Utilities, Biotechnology Stocks
Dividend Channel Staff - Tuesday, January 23, 1:38 PMIn trading on Tuesday, gas utilities shares were relative leaders, up on the day by about 1.2%. Leading the group were shares of Chesapeake Utilities Corporation (CPK), up about 4.7% and shares of South Jersey Industries (SJI) up about 3% on the day. Read More »
Wednesday Sector Laggards: Biotechnology, Drugs
Dividend Channel Staff - Wednesday, October 12, 12:10 PMIn trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 1.4%. Helping drag down the group were shares of Nymox Pharmaceutical (NYMX), off about 6.5% and shares of Fate Therapeutics (FATE) off about 6.1% on the day. Read More »
Wednesday Sector Laggards: Biotechnology, Drugs
Dividend Channel Staff - Wednesday, February 3, 1:12 PMIn trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Fate Therapeutics (FATE), off about 12.2% and shares of Vascular Biogenics (VBLT) off about 9.6% on the day. Read More »
|
A Brief Dividend History Top Dividends Opting for the Cash Dividend What is a Dividend? Dividend Calculator Dividend Yield Traps to Avoid Dividend Paying Stocks High Yield Stocks Paying Monthly Dividend Stocks: Their Importance Dividend ETFs High Dividend Stocks Paying Quarterly Dividend Aristocrats List Top Dividend Stocks YTD
Other news: News from PR Newswire |
|